Evoke Pharma, Inc. (EVOK)
NASDAQ: EVOK · Real-Time Price · USD
3.464
-0.031 (-0.88%)
Jun 5, 2025, 4:00 PM - Market closed

Evoke Pharma Statistics

Total Valuation

Evoke Pharma has a market cap or net worth of $7.00 million. The enterprise value is -$424,328.

Market Cap 7.00M
Enterprise Value -424,328

Important Dates

The last earnings date was Tuesday, May 13, 2025, after market close.

Earnings Date May 13, 2025
Ex-Dividend Date n/a

Share Statistics

Evoke Pharma has 2.02 million shares outstanding. The number of shares has increased by 491.05% in one year.

Current Share Class 1.49M
Shares Outstanding 2.02M
Shares Change (YoY) +491.05%
Shares Change (QoQ) -26.66%
Owned by Insiders (%) 0.99%
Owned by Institutions (%) 5.19%
Float 1.32M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 0.71
Forward PS 1.82
PB Ratio 1.21
P/TBV Ratio 1.21
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.55, with a Debt / Equity ratio of 0.88.

Current Ratio 1.55
Quick Ratio 1.45
Debt / Equity 0.88
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -10.01

Financial Efficiency

Return on equity (ROE) is -108.77% and return on invested capital (ROIC) is -32.11%.

Return on Equity (ROE) -108.77%
Return on Assets (ROA) -21.70%
Return on Invested Capital (ROIC) -32.11%
Return on Capital Employed (ROCE) -84.47%
Revenue Per Employee $3.86M
Profits Per Employee -$1.69M
Employee Count 3
Asset Turnover 0.80
Inventory Turnover 0.55

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -42.27% in the last 52 weeks. The beta is 0.02, so Evoke Pharma's price volatility has been lower than the market average.

Beta (5Y) 0.02
52-Week Price Change -42.27%
50-Day Moving Average 2.90
200-Day Moving Average 4.21
Relative Strength Index (RSI) 56.24
Average Volume (20 Days) 12,127

Short Selling Information

The latest short interest is 27,315, so 1.35% of the outstanding shares have been sold short.

Short Interest 27,315
Short Previous Month 24,685
Short % of Shares Out 1.35%
Short % of Float 2.06%
Short Ratio (days to cover) 1.92

Income Statement

In the last 12 months, Evoke Pharma had revenue of $11.59 million and -$5.08 million in losses. Loss per share was -$2.16.

Revenue 11.59M
Gross Profit 11.29M
Operating Income -5.00M
Pretax Income -7.13M
Net Income -5.08M
EBITDA n/a
EBIT -5.00M
Loss Per Share -$2.16
Full Income Statement

Balance Sheet

The company has $12.62 million in cash and $5.14 million in debt, giving a net cash position of $7.48 million or $3.70 per share.

Cash & Cash Equivalents 12.62M
Total Debt 5.14M
Net Cash 7.48M
Net Cash Per Share $3.70
Equity (Book Value) 5.84M
Book Value Per Share 2.89
Working Capital 5.78M
Full Balance Sheet

Cash Flow

Operating Cash Flow -3.88M
Capital Expenditures n/a
Free Cash Flow n/a
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross margin is 97.36%, with operating and profit margins of -43.17% and -43.80%.

Gross Margin 97.36%
Operating Margin -43.17%
Pretax Margin -43.80%
Profit Margin -43.80%
EBITDA Margin n/a
EBIT Margin -43.17%
FCF Margin n/a

Dividends & Yields

Evoke Pharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -491.05%
Shareholder Yield -491.05%
Earnings Yield -71.99%
FCF Yield n/a

Analyst Forecast

Price Target n/a
Price Target Difference n/a
Analyst Consensus n/a
Analyst Count n/a
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on August 1, 2024. It was a reverse split with a ratio of 0.0833333:1.

Last Split Date Aug 1, 2024
Split Type Reverse
Split Ratio 0.0833333:1

Scores

Evoke Pharma has an Altman Z-Score of -10.55 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -10.55
Piotroski F-Score 4